{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:38:45Z","timestamp":1794299925983,"version":"4.9.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41582-026-01260-5","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:45Z","timestamp":1788273825000},"page":"682-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Symptomatic treatment for Alzheimer disease: current evidence and future directions"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-5632","authenticated-orcid":false,"given":"Clive","family":"Ballard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-3731","authenticated-orcid":false,"given":"Zahinoor","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0586","author":"J Cummings","year":"2024","unstructured":"Cummings, J., Lanctot, K., Grossberg, G. & Ballard, C. Progress in pharmacologic management of neuropsychiatric syndromes in neurodegenerative disorders: a review. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0586 (2024).","journal-title":"JAMA Neurol."},{"key":"1260_CR2","first-page":"e70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings J. L. et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement. 11, e70098 (2025);","journal-title":"Alzheimers Dement."},{"key":"1260_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16049","author":"R Perneczky","year":"2024","unstructured":"Perneczky, R., Dom, G., Chan, A., Falkai, P. & Bassetti, C. Anti-amyloid antibody treatments for Alzheimer\u2019s disease. Eur. J. Neurol. https:\/\/doi.org\/10.1111\/ene.16049 (2024).","journal-title":"Eur. J. Neurol."},{"key":"1260_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.12923","author":"LD Baker","year":"2024","unstructured":"Baker, L. D. et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA https:\/\/doi.org\/10.1001\/jama.2025.12923 (2024).","journal-title":"JAMA"},{"key":"1260_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105173","author":"D Lee","year":"2024","unstructured":"Lee, D., Clark, E. D., Antonsdottir, I. M. & Porsteinsson, A. P. Brexpiprazole for agitation associated with dementia due to Alzheimer\u2019s disease. J. Am. Med. Dir. Assoc. https:\/\/doi.org\/10.1016\/j.jamda.2024.105173 (2024).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1260_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100329","volume":"12","author":"C Ballard","year":"2025","unstructured":"Ballard, C., Sultana, J., Doherty, P., Williams, G. & Corbett, A. Identifying synergistic combinations of repurposed treatments for Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 12, 100329 https:\/\/doi.org\/10.1016\/j.tjpad.2025.100329 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","volume":"20","author":"L Blanco-Silvente","year":"2017","unstructured":"Blanco-Silvente, L. et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16,106 patients. Int. J. Neuropsychopharmacol. 20, 519\u2013528 https:\/\/doi.org\/10.1093\/ijnp\/pyx012 (2017).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1260_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184","author":"MM Mielke","year":"2024","unstructured":"Mielke, M. M. et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.14184 (2024).","journal-title":"Alzheimers Dement."},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2318-11-55","volume":"11","author":"NJ Gates","year":"2011","unstructured":"Gates, N. J., Sachdev, P. S., Fiatarone Singh, M. A. & Valenzuela, M. Cognitive and memory training in adults at risk of dementia: a systematic review. BMC Geriatr. 11, 55 (2011).","journal-title":"BMC Geriatr."},{"key":"1260_CR10","doi-asserted-by":"publisher","first-page":"e027062","DOI":"10.1136\/bmjopen-2018-027062","volume":"9","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis. BMJ Open 9, e027062 (2019).","journal-title":"BMJ Open"},{"key":"1260_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5114\/areh.2025.149343","volume":"39","author":"S Sahaf","year":"2025","unstructured":"Sahaf, S., Salimi, Z. & Bidaki, R. Non-pharmacological interventions targeting working memory in mild cognitive impairment: a systematic review and meta-analysis. Adv. Rehabil. 39, 46\u201362 (2025).","journal-title":"Adv. Rehabil."},{"key":"1260_CR12","doi-asserted-by":"publisher","first-page":"e38624","DOI":"10.2196\/38624","volume":"24","author":"R Li","year":"2022","unstructured":"Li, R., Geng, J., Yang, R., Ge, Y. & Hesketh, T. Effectiveness of computerized cognitive training in delaying cognitive function decline in people with mild cognitive impairment: systematic review and meta-analysis. J. Med. Internet Res. 24, e38624 (2022).","journal-title":"J. Med. Internet Res."},{"key":"1260_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/bs16010040","volume":"16","author":"M Jiao","year":"2025","unstructured":"Jiao, M. et al. The effects of computerized cognitive training via tablet and computer platforms on cognitive function in patients with mild cognitive impairment: a systematic review and meta-analysis. Behav. Sci. 16, 40 (2025).","journal-title":"Behav. Sci."},{"key":"1260_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00987-5","volume":"7","author":"AT Chan","year":"2024","unstructured":"Chan, A. T., Ip, R. T., Tran, J. Y., Chan, J. Y. & Tsoi, K. K. Computerized cognitive training for memory functions in mild cognitive impairment or dementia: a systematic review and meta-analysis. npj Digit. Med. 7, 1 (2024).","journal-title":"npj Digit. Med."},{"key":"1260_CR15","doi-asserted-by":"publisher","unstructured":"Devanand, D. P. et al. Computerized games versus crosswords training in mild cognitive impairment. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200121 (2022).","DOI":"10.1056\/evidoa2200121"},{"key":"1260_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0447.2006.00789.x","volume":"114","author":"DI Sitzer","year":"2006","unstructured":"Sitzer, D. I., Twamley, E. W. & Jeste, D. V. Cognitive training in Alzheimer\u2019s disease: a meta-analysis of the literature. Acta Psychiatr. Scand. 114, 75\u201390 (2006).","journal-title":"Acta Psychiatr. Scand."},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"e005247","DOI":"10.1136\/bmjopen-2014-005247","volume":"5","author":"J Huntley","year":"2015","unstructured":"Huntley, J., Gould, R., Liu, K., Smith, M. & Howard, R. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open 5, e005247 (2015).","journal-title":"BMJ Open"},{"key":"1260_CR18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3233\/JAD-160810","volume":"56","author":"E-L Kallio","year":"2017","unstructured":"Kallio, E.-L., \u00d6hman, H., Kautiainen, H., Hietanen, M. & Pitk\u00e4l\u00e4, K. Cognitive training interventions for patients with Alzheimer\u2019s disease: a systematic review. J. Alzheimers Dis. 56, 1349\u20131372 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/13872877241289396","volume":"102","author":"M Tang","year":"2024","unstructured":"Tang, M. et al. Progress of research and application of non-pharmacologic intervention in Alzheimer\u2019s disease. J. Alzheimers Dis. 102, 275\u2013294 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00341-5","volume":"12","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction. Transl. Neurodegener. 12, 9 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/13872877251321176","volume":"104","author":"M Jia","year":"2025","unstructured":"Jia, M. et al. Effects of exercise on older adults with mild cognitive impairment: a systematic review and network meta-analysis. J. Alzheimers Dis. 104, 980\u2013994 (2025).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70734","volume":"15","author":"C Qiu","year":"2025","unstructured":"Qiu, C. et al. Comparison of the efficacy of different exercise modes on MCI adults: a network meta-analysis. Brain Behav. 15, e70734 (2025).","journal-title":"Brain Behav."},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jshs.2021.05.003","volume":"11","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Comparative efficacy of various exercise interventions on cognitive function in patients with mild cognitive impairment or dementia: a systematic review and network meta-analysis. J. Sport Health Sci. 11, 212\u2013223 (2022).","journal-title":"J. Sport Health Sci."},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/jocn.70067","volume":"35","author":"Z Deng","year":"2025","unstructured":"Deng, Z., Zeng, D., Zhang, Y., Jia, D. & Huang, X. Comparative effectiveness of multicomponent exercise interventions on cognitive function in people with cognitive impairmsent: a systematic review and network meta-analysis. J. Clin. Nurs. 35,631\u2013642 (2025).","journal-title":"J. Clin. Nurs."},{"key":"1260_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1436499","volume":"15","author":"Y Yu","year":"2024","unstructured":"Yu, Y., Wang, J. & Xu, J. Optimal dose and type of exercise to improve cognitive function in patients with mild cognitive impairment: a systematic review and network meta-analysis of RCTs. Front. Psychiatry 15, 1436499 (2024).","journal-title":"Front. Psychiatry"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12877-024-05060-8","volume":"24","author":"Y Yuan","year":"2024","unstructured":"Yuan, Y. et al. Effective dosage and mode of exercise for enhancing cognitive function in Alzheimer\u2019s disease and dementia: a systematic review and Bayesian model-based network meta-analysis of RCTs. BMC Geriatr. 24, 480 (2024).","journal-title":"BMC Geriatr."},{"key":"1260_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1643957","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y. et al. Effects of different physical activity interventions on executive function in older adults with dementia: a systematic review and network meta-analysis. Front. Neurol. 16, 1643957 (2025).","journal-title":"Front. Neurol."},{"key":"1260_CR28","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1080\/13607863.2021.2019192","volume":"26","author":"A Begde","year":"2022","unstructured":"Begde, A., Jain, M., Hogervorst, E. & Wilcockson, T. Does physical exercise improve the capacity for independent living in people with dementia or mild cognitive impairment: an overview of systematic reviews and meta-analyses. Aging Ment. Health 26, 2317\u20132327 (2022).","journal-title":"Aging Ment. Health"},{"key":"1260_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1391611","volume":"16","author":"C Liu","year":"2024","unstructured":"Liu, C., Gao, S. & Li, S. The effect of physical exercise intervention on the ability of daily living in patients with Alzheimer\u2019s dementia: a meta-analysis. Front. Aging Neurosci. 16, 1391611 (2024).","journal-title":"Front. Aging Neurosci."},{"key":"1260_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1485807","volume":"12","author":"Y Xiao","year":"2024","unstructured":"Xiao, Y., Fan, Y. & Feng, Z. A meta-analysis of the efficacy of physical exercise interventions on activities of daily living in patients with Alzheimer\u2019s disease. Front. Public Health 12, 1485807 (2024).","journal-title":"Front. Public Health"},{"key":"1260_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13195-023-01286-7","volume":"15","author":"W Li","year":"2023","unstructured":"Li, W. et al. Cost-effectiveness of physical activity interventions for prevention and management of cognitive decline and dementia \u2014 a systematic review. Alzheimers Res. Ther. 15, 159 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"1260_CR32","doi-asserted-by":"publisher","unstructured":"R\u00f6hr, S. et al. How can urban environments support dementia risk reduction? A qualitative study. Int. J. Geriatr. Psychiatry https:\/\/doi.org\/10.1002\/gps.5626 (2022).","DOI":"10.1002\/gps.5626"},{"key":"1260_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2023.104493","volume":"143","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Barriers and motivators to promotion of physical activity participation for older adults with mild cognitive impairment or dementia: an umbrella review. Int. J. Nurs. Stud. 143, 104493 (2023).","journal-title":"Int. J. Nurs. Stud."},{"key":"1260_CR34","doi-asserted-by":"publisher","first-page":"e090767","DOI":"10.1136\/bmjopen-2024-090767","volume":"15","author":"LH Chen","year":"2025","unstructured":"Chen, L. H. et al. Effectiveness of cognitive stimulation for individuals with mild cognitive impairment: a systematic review and meta-analysis. BMJ Open 15, e090767 (2025).","journal-title":"BMJ Open"},{"key":"1260_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2022.104181","volume":"128","author":"ID Saragih","year":"2022","unstructured":"Saragih, I. D., Tonapa, S. I., Saragih, I. S. & Lee, B.-O. Effects of cognitive stimulation therapy for people with dementia: a systematic review and meta-analysis of randomized controlled studies. Int. J. Nurs. Stud. 128, 104181 (2022).","journal-title":"Int. J. Nurs. Stud."},{"key":"1260_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100207","volume":"12","author":"L-B Liang","year":"2025","unstructured":"Liang, L.-B, Wang, S., Li, K.-P & Wu, C.-Q. Comparative efficacy of cognitive training modalities in cognitive impairment: a systematic review and network meta-analysis. J. Prev. Alzheimers Dis. 12, 100207 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1260_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-02032-0","volume":"11","author":"N Tulliani","year":"2022","unstructured":"Tulliani, N., Bissett, M., Fahey, P., Bye, R. & Liu, K. P. Efficacy of cognitive remediation on activities of daily living in individuals with mild cognitive impairment or early-stage dementia: a systematic review and meta-analysis. Syst. Rev. 11, 156 (2022).","journal-title":"Syst. Rev."},{"key":"1260_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1037\/bul0000325","volume":"147","author":"RM Cafferata","year":"2021","unstructured":"Cafferata, R. M., Hicks, B. & von Bastian, C. C. Effectiveness of cognitive stimulation for dementia: a systematic review and meta-analysis. Psychol. Bull. 147, 455 (2021).","journal-title":"Psychol. Bull."},{"key":"1260_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102312","volume":"97","author":"R Desai","year":"2024","unstructured":"Desai, R. et al. Effectiveness of cognitive stimulation therapy (CST) for mild to moderate dementia: a systematic literature review and meta-analysis of randomised control trials using the original CST protocol. Ageing Res. Rev. 97, 102312 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1260_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/03080226231156517","volume":"86","author":"S Ryan","year":"2023","unstructured":"Ryan, S. & Brady, O. Cognitive stimulation and activities of daily living for individuals with mild-to-moderate dementia: a scoping review. Br. J. Occup. Ther. 86, 540\u2013559 (2023).","journal-title":"Br. J. Occup. Ther."},{"key":"1260_CR41","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1177\/01939459211032272","volume":"44","author":"S Ahn","year":"2022","unstructured":"Ahn, S., Chung, J. W., Crane, M. K., Bassett, J.rD. R. & Anderson, J. G. The effects of multi-domain interventions on cognition: a systematic review. West. J. Nurs. Res. 44, 1134\u20131154 (2022).","journal-title":"West. J. Nurs. Res."},{"key":"1260_CR42","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255\u20132263 (2015).","journal-title":"Lancet"},{"key":"1260_CR43","doi-asserted-by":"publisher","first-page":"e70556","DOI":"10.1002\/alz.70556","volume":"21","author":"MC Carrillo","year":"2025","unstructured":"Carrillo, M. C., Snyder, H. M., Baumgart, M. & Pike, K. J. What the US POINTER results mean for public health initiatives and the Alzheimer\u2019s Association. Alzheimers Dement. 21, e70556 (2025).","journal-title":"Alzheimers Dement."},{"key":"1260_CR44","first-page":"e70180","volume":"11","author":"A Alfini","year":"2025","unstructured":"Alfini, A. & Dougherty, R. J. Lifestyle medicine and brain health: insights from the US study to protect brain health through lifestyle intervention to reduce risk (US POINTER) and the promise of personalization. Alzheimers Dement. 11, e70180 (2025).","journal-title":"Alzheimers Dement."},{"key":"1260_CR45","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3390\/jcm14072261","volume":"14","author":"E V\u00e1squez-Carrasco","year":"2025","unstructured":"V\u00e1squez-Carrasco, E. et al. Effectiveness of combined cognitive stimulation and physical activity interventions on activities of daily living, cognitive function, and physical function in older people with mild cognitive impairment: a systematic review with meta-analysis. J. Clin. Med. 14, 2261 (2025).","journal-title":"J. Clin. Med."},{"key":"1260_CR46","doi-asserted-by":"publisher","first-page":"e70291","DOI":"10.2196\/70291","volume":"8","author":"RC-F Chan","year":"2025","unstructured":"Chan, R. C.-F. et al. Nonpharmacological multimodal interventions for cognitive functions in older adults with mild cognitive impairment: scoping review. JMIR Aging 8, e70291 (2025).","journal-title":"JMIR Aging"},{"key":"1260_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/13607863.2025.2602664","volume":"30","author":"R Huang","year":"2025","unstructured":"Huang, R. et al. The effectiveness of non-pharmacological community dementia prevention interventions on older adults with mild cognitive impairment in China: a systematic review and meta-analysis. Aging Ment. Health 30, 655\u2013669 (2025).","journal-title":"Aging Ment. Health"},{"key":"1260_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2025.106049","volume":"140","author":"TA Rookes","year":"2025","unstructured":"Rookes, T. A. et al. Evidence for health promotion interventions to improve cognitive and physical functioning outcomes in older adults with MCI: a state-of-the-art review. Arch. Gerontol. Geriatr. 140, 106049 (2025).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"1260_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13024-025-00912-2","volume":"20","author":"JC Roach","year":"2025","unstructured":"Roach, J. C. et al. Multidomain therapy for Alzheimer\u2019s disease: a scoping review of cognitive decline trials. Mol. Neurodegener. 20, 125 (2025).","journal-title":"Mol. Neurodegener."},{"key":"1260_CR50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1471301218795289","volume":"19","author":"G Chalfont","year":"2020","unstructured":"Chalfont, G., Milligan, C. & Simpson, J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia 19, 1086\u20131130 (2020).","journal-title":"Dementia"},{"key":"1260_CR51","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s12603-023-2046-2","volume":"27","author":"CB Castro","year":"2023","unstructured":"Castro, C. B. et al. Multi-domain interventions for dementia prevention \u2014 a systematic review. J. Nutr. Health Aging 27, 1271\u20131280 (2023).","journal-title":"J. Nutr. Health Aging"},{"key":"1260_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","volume":"388","author":"EP Moll van Charante","year":"2016","unstructured":"Moll van Charante, E. P. et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet 388, 797\u2013805 https:\/\/doi.org\/10.1016\/S0140-6736(16)30950-3 (2016).","journal-title":"Lancet"},{"key":"1260_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/14713012251412051","volume":"24","author":"E Gebran","year":"2025","unstructured":"Gebran, E., Antoniou, M., Samtani, S., Brookman, R. & Siette, J. Barriers and facilitators to implementing non-pharmacological dementia therapies in residential aged care: a systematic review. Dementia 24, 14713012251412051 (2025).","journal-title":"Dementia"},{"key":"1260_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12984-025-01566-3","volume":"22","author":"M Wu","year":"2025","unstructured":"Wu, M. et al. Efficacy of non-invasive brain stimulation interventions on cognitive impairment: an umbrella review of meta-analyses of randomized controlled trials. J. Neuroeng. Rehabil. 22, 22 (2025).","journal-title":"J. Neuroeng. Rehabil."},{"key":"1260_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12984-025-01842-2","volume":"23","author":"C Wang","year":"2026","unstructured":"Wang, C. et al. Efficacy of non-invasive neuromodulation technologies in improving cognitive function and activities of daily living in patients with Alzheimer\u2019s disease, Parkinson\u2019s disease, and stroke: a systematic review and network meta-analysis. J. Neuroeng. Rehabil. 23, 46 (2026).","journal-title":"J. Neuroeng. Rehabil."},{"key":"1260_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jpsychires.2025.09.072","volume":"191","author":"Y Cai","year":"2025","unstructured":"Cai, Y. et al. Effects of different non-invasive brain stimulation interventions on cognitive and functional abilities in people with mild cognitive impairment and dementia: a systematic review and meta-analysis. J. Psychiatr. Res. 191, 470\u2013481 (2025).","journal-title":"J. Psychiatr. Res."},{"key":"1260_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1659208","volume":"12","author":"E V\u00e1squez-Carrasco","year":"2025","unstructured":"V\u00e1squez-Carrasco, E. et al. Effects of non-invasive brain stimulation combined with cognitive training on cognitive functions in older people with mild cognitive impairment: a systematic review with meta-analysis. Front. Med. 12, 1659208 (2025).","journal-title":"Front. Med."},{"key":"1260_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10072-024-07709-z","volume":"46","author":"Y Hou","year":"2025","unstructured":"Hou, Y., Liu, F., Lin, N. & Gao, S. Systematic review and meta-analysis of repetitive transcranial magnetic stimulation (rTMS) for activities of daily living in Alzheimer\u2019s disease. Neurol. Sci. 46, 63\u201377 (2025).","journal-title":"Neurol. Sci."},{"key":"1260_CR59","first-page":"CD009132","volume":"2012","author":"TC Russ","year":"2012","unstructured":"Russ, T. C. & Morling, J. R. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst. Rev. 2012, CD009132 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1260_CR60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-190546","volume":"71","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga, S., Fujishiro, H. & Takechi, H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J. Alzheimers Dis. 71, 513\u2013523 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR61","doi-asserted-by":"publisher","first-page":"e053012","DOI":"10.1136\/bmjopen-2021-053012","volume":"12","author":"AA Veroniki","year":"2022","unstructured":"Veroniki, A. A. et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer\u2019s dementia: a systematic review with individual patient data network meta-analysis. BMJ Open 12, e053012 (2022).","journal-title":"BMJ Open"},{"key":"1260_CR62","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard, R. et al. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N. Engl. J. Med. 366, 893\u2013903 https:\/\/doi.org\/10.1056\/NEJMoa1106668 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR63","unstructured":"UK Parliament Select Committee on Health. Evidence Submitted by the Alzheimer\u2019s Society (NICE 70) https:\/\/publications.parliament.uk\/pa\/cm200607\/cmselect\/cmhealth\/503\/503we05.htm (2007)."},{"key":"1260_CR64","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1503\/cmaj.051432","volume":"174","author":"K Rockwood","year":"2006","unstructured":"Rockwood, K., Fay, S., Song, X., MacKnight, C. & Gorman, M. Attainment of treatment goals by people with Alzheimer\u2019s disease receiving galantamine: a randomized controlled trial. CMAJ 174, 1099\u20131105 https:\/\/doi.org\/10.1503\/cmaj.051432 (2006).","journal-title":"CMAJ"},{"key":"1260_CR65","doi-asserted-by":"publisher","first-page":"e37799","DOI":"10.1097\/MD.0000000000037799","volume":"103","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Lai, M. & Tao, M. Evaluating the efficacy and safety of Alzheimer\u2019s disease drugs: a meta-analysis and systematic review. Medicine 103, e37799 https:\/\/doi.org\/10.1097\/MD.0000000000037799 (2024).","journal-title":"Medicine"},{"key":"1260_CR66","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/gps.5522","volume":"36","author":"F Yasuno","year":"2021","unstructured":"Yasuno, F. & Minami, H. Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer\u2019s disease continuum: an in vivo positron emission tomography study. Int. J. Geriatr. Psychiatry 36, 1274\u20131283 (2021).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"1260_CR67","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13195-024-01580-y","volume":"16","author":"J-M Pyun","year":"2024","unstructured":"Pyun, J.-M., Park, Y. H., Kang, M. J. & Kim, S. Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes. Alzheimers Res. Ther. 16, 210 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1260_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.998224","volume":"16","author":"FE Pozzi","year":"2022","unstructured":"Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C. & Tremolizzo, L. Predictors of response to acetylcholinesterase inhibitors in dementia: a systematic review. Front. Neurosci. 16, 998224 (2022).","journal-title":"Front. Neurosci."},{"key":"1260_CR69","doi-asserted-by":"publisher","first-page":"e31625","DOI":"10.1097\/MD.0000000000031625","volume":"101","author":"RE Nielsen","year":"2022","unstructured":"Nielsen, R. E., Gr\u00f8ntved, S., Lolk, A., Andersen, K. & Valentin, J. B. Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer\u00b4s dementia. Medicine 101, e31625 (2022).","journal-title":"Medicine"},{"key":"1260_CR70","first-page":"CD009081","volume":"3","author":"C Parsons","year":"2021","unstructured":"Parsons, C. et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 3, CD009081 (2021).","journal-title":"Cochrane Database Syst Rev."},{"key":"1260_CR71","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s41999-025-01398-3","volume":"17","author":"P Rattanatanyapat","year":"2026","unstructured":"Rattanatanyapat, P., Suan-Ek, P., Saokaew, S., Phisalprapa, P. & Mongkhon, P. Antidementia drugs and nursing home placement: a systematic review and meta-analysis. Eur. Geriatr. Med. 17, 589\u2013605 (2026).","journal-title":"Eur. Geriatr. Med."},{"key":"1260_CR72","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 16, 661\u2013673 https:\/\/doi.org\/10.1038\/s41582-020-0397-4 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1260_CR73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick, N. C. et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465\u2013473 https:\/\/doi.org\/10.1001\/archneur.1997.00550160091022 (1997).","journal-title":"Arch. Neurol."},{"key":"1260_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane, S. et al. Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial. J. Prev. Alzheimers Dis. 12, 100016 https:\/\/doi.org\/10.1016\/j.tjpad.2024.100016 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1260_CR75","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/cells10081871","volume":"10","author":"M Dahlstr\u00f6m","year":"2021","unstructured":"Dahlstr\u00f6m, M. et al. Identification of novel positive allosteric modulators of neurotrophin receptors for the treatment of cognitive dysfunction. Cells 10, 1871 https:\/\/doi.org\/10.3390\/cells10081871 (2021).","journal-title":"Cells"},{"key":"1260_CR76","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13195-025-01895-4","volume":"17","author":"A Corbett","year":"2025","unstructured":"Corbett, A. et al. Drug repurposing for Alzheimer\u2019s disease: a Delphi consensus and stakeholder consultation. Alzheimers Res. Ther. 17, 237 https:\/\/doi.org\/10.1186\/s13195-025-01895-4 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"1260_CR77","doi-asserted-by":"publisher","first-page":"pyu115","DOI":"10.1093\/ijnp\/pyu115","volume":"18","author":"S Matsunaga","year":"2014","unstructured":"Matsunaga, S., Kishi, T. & Iwata, N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 18, pyu115 https:\/\/doi.org\/10.1093\/ijnp\/pyu115 (2014).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1260_CR78","doi-asserted-by":"publisher","unstructured":"Farrimond, L. E., Roberts, E. & McShane, R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer\u2019s disease: a systematic review. BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2012-000917 (2012).","DOI":"10.1136\/bmjopen-2012-000917"},{"key":"1260_CR79","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","volume":"38","author":"JL Cummings","year":"2024","unstructured":"Cummings, J. L., Osse, A. M. L., Kinney, J. W., Cammann, D. & Chen, J. Alzheimer\u2019s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs 38, 613\u2013624 https:\/\/doi.org\/10.1007\/s40263-024-01103-1 (2024).","journal-title":"CNS Drugs"},{"key":"1260_CR80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.14283\/jpad.2019.12","volume":"6","author":"S Gauthier","year":"2019","unstructured":"Gauthier, S. et al. Combination therapy for Alzheimer\u2019s disease: perspectives of the EU\/US CTAD Task Force. J. Prev. Alzheimers Dis. 6, 164\u2013168 https:\/\/doi.org\/10.14283\/jpad.2019.12 (2019).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1260_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 https:\/\/doi.org\/10.1056\/NEJMoa2212948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR82","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 https:\/\/doi.org\/10.1001\/jama.2023.13239 (2023).","journal-title":"JAMA"},{"key":"1260_CR83","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/03007995.2025.2552278","volume":"41","author":"J Stroud","year":"2025","unstructured":"Stroud, J. et al. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer\u2019s disease. Curr. Med. Res. Opin. 41, 1523\u20131534 https:\/\/doi.org\/10.1080\/03007995.2025.2552278 (2025).","journal-title":"Curr. Med. Res. Opin."},{"key":"1260_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/oalib.1112714","volume":"12","author":"T Katkar","year":"2025","unstructured":"Katkar, T. BDNF gene therapy: a potential solution for neurodegenerative diseases. Open Access Libr. J. 12, 1\u201317 https:\/\/doi.org\/10.4236\/oalib.1112714 (2025).","journal-title":"Open Access Libr. J."},{"key":"1260_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00415-025-13456-8","volume":"272","author":"X Guo","year":"2025","unstructured":"Guo, X. et al. Advances of therapeutic strategies for Alzheimer\u2019s disease. J. Neurol. 272, 705 https:\/\/doi.org\/10.1007\/s00415-025-13456-8 (2025).","journal-title":"J. Neurol."},{"key":"1260_CR86","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.ajpath.2025.05.020","volume":"195","author":"A Djurovic-Topalovic","year":"2025","unstructured":"Djurovic-Topalovic, A., Horgan, N. G. & Fortin, J. S. Updates on tau-related drug targets and potential disease-modifying therapies for Alzheimer\u2019s disease. Am. J. Pathol. 195, 1975\u20131987 https:\/\/doi.org\/10.1016\/j.ajpath.2025.05.020 (2025).","journal-title":"Am. J. Pathol."},{"key":"1260_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen, Y. & Yu, Y. Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J. Neuroinflammation 20, 165 https:\/\/doi.org\/10.1186\/s12974-023-02853-3 (2023).","journal-title":"J. Neuroinflammation"},{"key":"1260_CR88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000110738","volume":"24","author":"P Aalten","year":"2007","unstructured":"Aalten, P. et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dementia Geriatr. Cogn. Disord. 24, 457\u2013463 (2007).","journal-title":"Dementia Geriatr. Cogn. Disord."},{"key":"1260_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00597-3","author":"Z Ismail","year":"2022","unstructured":"Ismail, Z. et al. Psychosis in Alzheimer disease \u2014 mechanisms, genetics and therapeutic opportunities. Nat. Rev. Neurol. https:\/\/doi.org\/10.1038\/s41582-021-00597-3 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1260_CR90","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610214000131","author":"I Testad","year":"2014","unstructured":"Testad, I. et al. The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. Int. Psychogeriatr. https:\/\/doi.org\/10.1017\/S1041610214000131 (2014).","journal-title":"Int. Psychogeriatr."},{"key":"1260_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2023.10.008","author":"YY Huang","year":"2024","unstructured":"Huang, Y. Y., Gan, Y. H., Yang, L., Cheng, W. & Yu, J. T. Depression in Alzheimer\u2019s disease: epidemiology, mechanisms, and treatment. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2023.10.008 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1260_CR92","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190365","author":"A Showraki","year":"2019","unstructured":"Showraki, A. et al. Cerebrospinal fluid correlates of neuropsychiatric symptoms in patients with Alzheimer\u2019s disease\/mild cognitive impairment: a systematic review. J. Alzheimers Dis. https:\/\/doi.org\/10.3233\/JAD-190365 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.inpsyc.2025.100118","author":"C Ballard","year":"2025","unstructured":"Ballard, C. et al. Brief operationalized psychosocial interventions for agitation and psychosis: use in clinical trials and clinical care. Int. Psychogeriatr. https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100118 (2025).","journal-title":"Int. Psychogeriatr."},{"key":"1260_CR94","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/62.8.908","author":"J Cohen-Mansfield","year":"2007","unstructured":"Cohen-Mansfield, J., Libin, A. & Marx, M. S. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J. Gerontol. A, Biol. Sci. Med. Sci. https:\/\/doi.org\/10.1093\/gerona\/62.8.908 (2007).","journal-title":"J. Gerontol. A, Biol. Sci. Med. Sci."},{"key":"1260_CR95","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15010130","author":"C Ballard","year":"2016","unstructured":"Ballard, C. et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People With Dementia (WHELD) program. Am. J. Psychiatry https:\/\/doi.org\/10.1176\/appi.ajp.2015.15010130 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"1260_CR96","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.15.2015","author":"L Teri","year":"2003","unstructured":"Teri, L. et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA https:\/\/doi.org\/10.1001\/jama.290.15.2015 (2003).","journal-title":"JAMA"},{"key":"1260_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2016.04.006","author":"AP Rajkumar","year":"2016","unstructured":"Rajkumar, A. P. et al. Apathy and its response to antipsychotic review and nonpharmacological interventions in people with dementia living in nursing homes: WHELD, a factorial cluster randomized controlled trial. J. Am. Med. Dir. Assoc. https:\/\/doi.org\/10.1016\/j.jamda.2016.04.006 (2016).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1260_CR98","doi-asserted-by":"publisher","DOI":"10.1111\/inm.13254","author":"Z Yin","year":"2024","unstructured":"Yin, Z. et al. Comparative efficacy of multiple non-pharmacological interventions for behavioural and psychological symptoms of dementia: a network meta-analysis of randomised controlled trials. Int. J. Ment. Health Nurs. https:\/\/doi.org\/10.1111\/inm.13254 (2024).","journal-title":"Int. J. Ment. Health Nurs."},{"key":"1260_CR99","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jamda.2022.02.016","volume":"23","author":"J McDermid","year":"2022","unstructured":"McDermid, J. et al. A randomized controlled trial of a digital adaptation of the WHELD person-centered nursing home training program. J. Am. Med. Dir. Assoc. 23, 1166\u20131170 https:\/\/doi.org\/10.1016\/j.jamda.2022.02.016 (2022).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1260_CR100","doi-asserted-by":"publisher","first-page":"e1002500","DOI":"10.1371\/journal.pmed.1002500","volume":"15","author":"C Ballard","year":"2018","unstructured":"Ballard, C. et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med. 15, e1002500 https:\/\/doi.org\/10.1371\/journal.pmed.1002500 (2018).","journal-title":"PLoS Med."},{"key":"1260_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2020.08.008","author":"HC Kales","year":"2020","unstructured":"Kales, H. C., Kern, V., Kim, H. M. & Blazek, M. C. Moving evidence-informed assessment and management of behavioral and psychological symptoms of dementia into the real world: training family and staff caregivers in the dice approach. Am. J. Geriatr. Psychiatry https:\/\/doi.org\/10.1016\/j.jagp.2020.08.008 (2020).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1260_CR102","doi-asserted-by":"publisher","DOI":"10.1177\/15333175231160682","author":"KN Fong","year":"2023","unstructured":"Fong, K. N., Ge, X., Ting, K. H., Wei, M. & Cheung, H. The effects of light therapy on sleep, agitation and depression in people with dementia: a systematic review and meta-analysis of randomized controlled trials. Am. J. Alzheimers Dis. Other Dement. https:\/\/doi.org\/10.1177\/15333175231160682 (2023).","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"1260_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105199","author":"PH Wang","year":"2024","unstructured":"Wang, P. H. et al. Efficacy of aromatherapy against behavioral and psychological disturbances in people with dementia: a meta-analysis of randomized controlled trials. J. Am. Med. Dir. Assoc. https:\/\/doi.org\/10.1016\/j.jamda.2024.105199 (2024).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1260_CR104","doi-asserted-by":"publisher","DOI":"10.1159\/000324438","author":"A Burns","year":"2011","unstructured":"Burns, A. et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer\u2019s disease. Dement. Geriatr. Cognit. Disord. https:\/\/doi.org\/10.1159\/000324438 (2011).","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"1260_CR105","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4088\/jcp.v63n0703","volume":"63","author":"CG Ballard","year":"2002","unstructured":"Ballard, C. G., O\u2019Brien, J. T., Reichelt, K. & Perry, E. K. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J. Clin. Psychiatry 63, 553\u2013558 https:\/\/doi.org\/10.4088\/jcp.v63n0703 (2002).","journal-title":"J. Clin. Psychiatry"},{"key":"1260_CR106","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00019442-199522330-00003","volume":"3","author":"S Holroyd","year":"1995","unstructured":"Holroyd, S. & Sheldon-Keller, A. A study of visual hallucinations in Alzheimer\u2019s disease. Am. J. Geriatr. Psychiatry 3, 198\u2013205 https:\/\/doi.org\/10.1097\/00019442-199522330-00003 (1995).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1260_CR107","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160792","author":"A Adrait","year":"2017","unstructured":"Adrait, A. et al. Do hearing aids influence behavioral and psychological symptoms of dementia and quality of life in hearing impaired Alzheimer\u2019s disease patients and their caregivers? J. Alzheimers Dis. https:\/\/doi.org\/10.3233\/JAD-160792 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR108","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.12.1983","author":"FM Chapman","year":"1999","unstructured":"Chapman, F. M., Dickinson, J., McKeith, I. & Ballard, C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer\u2019s disease: treatment implications. Am. J. Psychiatry https:\/\/doi.org\/10.1176\/ajp.156.12.1983 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"1260_CR109","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg, G. T. et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am. J. Geriatr. Psychiatry 28, 383\u2013400 https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009 (2020).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1260_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07576-8","author":"G Marinheiro","year":"2024","unstructured":"Marinheiro, G. et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Neurological Sci. https:\/\/doi.org\/10.1007\/s10072-024-07576-8 (2024).","journal-title":"Neurological Sci."},{"key":"1260_CR111","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry_197_25","author":"JVA Fernandes","year":"2025","unstructured":"Fernandes, J. V. A., Ramos, J. V. O., Vilar, L. A. D. S. & Holanda, M. M. A. Brexpiprazole for agitation in Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials. Indian J. Psychiatry https:\/\/doi.org\/10.4103\/indianjpsychiatry_197_25 (2025).","journal-title":"Indian J. Psychiatry"},{"key":"1260_CR112","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrn1926","volume":"7","author":"C Ballard","year":"2006","unstructured":"Ballard, C. & Howard, R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci. 7, 492\u2013500 https:\/\/doi.org\/10.1038\/nrn1926 (2006).","journal-title":"Nat. Rev. Neurosci."},{"key":"1260_CR113","doi-asserted-by":"publisher","unstructured":"M\u00fchlbauer, V. et al.Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD013304.pub2 (2021).","DOI":"10.1002\/14651858.CD013304.pub2"},{"key":"1260_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1792","author":"I Katz","year":"2007","unstructured":"Katz, I. et al. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer\u2019s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int. J. Geriatric Psychiatry https:\/\/doi.org\/10.1002\/gps.1792 (2007).","journal-title":"Int. J. Geriatric Psychiatry"},{"key":"1260_CR115","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38369.459988.8F","author":"C Ballard","year":"2005","unstructured":"Ballard, C. et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: randomised double blind placebo controlled trial. Br. Med. J. https:\/\/doi.org\/10.1136\/bmj.38369.459988.8F (2005).","journal-title":"Br. Med. J."},{"key":"1260_CR116","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/s1041610201007499","volume":"13","author":"C Ballard","year":"2001","unstructured":"Ballard, C. et al. Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. Int. Psychogeriatr. 13, 93\u2013106 https:\/\/doi.org\/10.1017\/s1041610201007499 (2001).","journal-title":"Int. Psychogeriatr."},{"key":"1260_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.39","author":"CG Ballard","year":"2009","unstructured":"Ballard, C. G. et al. Management of agitation and aggression associated with Alzheimer disease. Nat. Rev. Neurol. https:\/\/doi.org\/10.1038\/nrneurol.2009.39 (2009).","journal-title":"Nat. Rev. Neurol."},{"key":"1260_CR118","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","volume":"165","author":"DL Sultzer","year":"2008","unstructured":"Sultzer, D. L. et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am. J. Psychiatry 165, 844\u2013854 https:\/\/doi.org\/10.1176\/appi.ajp.2008.07111779 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"1260_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000200589.01396.6d","author":"LS Schneider","year":"2006","unstructured":"Schneider, L. S., Dagerman, K. & Insel, P. S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatric Psychiatry https:\/\/doi.org\/10.1097\/01.JGP.0000200589.01396.6d (2006).","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"1260_CR120","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934","author":"LS Schneider","year":"2005","unstructured":"Schneider, L. S., Dagerman, K. S. & Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA https:\/\/doi.org\/10.1001\/jama.294.15.1934 (2005).","journal-title":"JAMA"},{"key":"1260_CR121","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider, L. S. et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N. Engl. J. Med. 355, 1525\u20131538 https:\/\/doi.org\/10.1056\/NEJMoa061240 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR122","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"C Ballard","year":"2005","unstructured":"Ballard, C. et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: randomised double blind placebo controlled trial. Br. Med. J. 330, 874 https:\/\/doi.org\/10.1136\/bmj.38369.459988.8F (2005).","journal-title":"Br. Med. J."},{"key":"1260_CR123","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s1474-4422(08)70295-3","volume":"8","author":"C Ballard","year":"2009","unstructured":"Ballard, C. et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 8, 151\u2013157 https:\/\/doi.org\/10.1016\/s1474-4422(08)70295-3 (2009).","journal-title":"Lancet Neurol."},{"key":"1260_CR124","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","volume":"367","author":"DP Devanand","year":"2012","unstructured":"Devanand, D. P. et al. Relapse risk after discontinuation of risperidone in Alzheimer\u2019s disease. N. Engl. J. Med. 367, 1497\u20131507 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668","author":"R Howard","year":"2012","unstructured":"Howard, R. et al. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1106668 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR126","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.532","author":"JL Cummings","year":"2004","unstructured":"Cummings, J. L., Schneider, L., Tariot, P. N., Kershaw, P. R. & Yuan, W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer\u2019s disease. Am. J. Psychiatry https:\/\/doi.org\/10.1176\/appi.ajp.161.3.532 (2004).","journal-title":"Am. J. Psychiatry"},{"key":"1260_CR127","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa066583","volume":"357","author":"RJ Howard","year":"2007","unstructured":"Howard, R. J. et al. Donepezil for the treatment of agitation in Alzheimer\u2019s disease. N. Engl. J. Med. 357, 1382\u20131392 https:\/\/doi.org\/10.1056\/NEJMoa066583 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4065","author":"BS Husebo","year":"2011","unstructured":"Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B. & Aarsland, D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. Br. Med. J. https:\/\/doi.org\/10.1136\/bmj.d4065 (2011).","journal-title":"Br. Med. J."},{"key":"1260_CR129","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson, A. P. et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA https:\/\/doi.org\/10.1001\/jama.2014.93 (2014).","journal-title":"JAMA"},{"key":"1260_CR130","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41591-025-03569-y","volume":"31","author":"TK Rajji","year":"2025","unstructured":"Rajji, T. K. et al. Escitalopram for agitation in Alzheimer\u2019s dementia: a randomized controlled phase 3 trial. Nat. Med. 31, 1586\u20131591 https:\/\/doi.org\/10.1038\/s41591-025-03569-y (2025).","journal-title":"Nat. Med."},{"key":"1260_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01210-1","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(21)01210-1 (2021).","journal-title":"Lancet"},{"key":"1260_CR132","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10214","author":"JL Cummings","year":"2015","unstructured":"Cummings, J. L. et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA https:\/\/doi.org\/10.1001\/jama.2015.10214 (2015).","journal-title":"JAMA"},{"key":"1260_CR133","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1882995","author":"R Khoury","year":"2021","unstructured":"Khoury, R. et al. AVP-786 as a promising treatment option for Alzheimer\u2019s disease including agitation. Expert Opin. Pharmacother. https:\/\/doi.org\/10.1080\/14656566.2021.1882995 (2021).","journal-title":"Expert Opin. Pharmacother."},{"key":"1260_CR134","unstructured":"FDA approves first non-antipsychotic drug to treat agitation associated with dementia. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia (2026)."},{"key":"1260_CR135","first-page":"5194","volume":"102","author":"J Cummings","year":"2024","unstructured":"Cummings, J., Grossberg, G., Andersson, C., Streicher, C. & Tabuteau, H. Efficacy and safety of AXS-05 in agitation associated with Alzheimer\u2019s disease: results from ACCORD, a phase 3, double-blind, placebo-controlled, relapse prevention trial. Neurol. J. 102, 5194 (2024).","journal-title":"Neurol. J."},{"key":"1260_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5813","author":"R Nirogi","year":"2022","unstructured":"Nirogi, R. et al. Potential beneficial effects of masupirdine (SUVN-502) on agitation\/aggression and psychosis in patients with moderate Alzheimer\u2019s disease: exploratory post hoc analyses. Int. J. Geriatric Psychiatry https:\/\/doi.org\/10.1002\/gps.5813 (2022).","journal-title":"Int. J. Geriatric Psychiatry"},{"key":"1260_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.05.002","author":"N Herrmann","year":"2019","unstructured":"Herrmann, N. et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease. Am. J. Geriatric Psychiatry https:\/\/doi.org\/10.1016\/j.jagp.2019.05.002 (2019).","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"1260_CR138","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/aog.0000000000004551","volume":"138","author":"B Hadaie","year":"2021","unstructured":"Hadaie, B. & Haas, D. M. Cochrane review summaries \u2014 October 2021. Obstet. Gynecol. 138, 675\u2013677 https:\/\/doi.org\/10.1097\/aog.0000000000004551 (2021).","journal-title":"Obstet. Gynecol."},{"key":"1260_CR139","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.13101","author":"E Mori","year":"2024","unstructured":"Mori, E., Ikeda, M. & Ohdake, M. Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies. Psychogeriatrics https:\/\/doi.org\/10.1111\/psyg.13101 (2024).","journal-title":"Psychogeriatrics"},{"key":"1260_CR140","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori, E., Ikeda, M. & Kosaka, K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann. Neurol. 72, 41\u201352 https:\/\/doi.org\/10.1002\/ana.23557 (2012).","journal-title":"Ann. Neurol."},{"key":"1260_CR141","doi-asserted-by":"publisher","DOI":"10.1159\/000077816","author":"IG McKeith","year":"2004","unstructured":"McKeith, I. G., Wesnes, K. A., Perry, E. & Ferrara, R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement. Geriatr. Cognit. Disord. https:\/\/doi.org\/10.1159\/000077816 (2004).","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"1260_CR142","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/s0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings, J. et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 383, 533\u2013540 https:\/\/doi.org\/10.1016\/s0140-6736(13)62106-6 (2014).","journal-title":"Lancet."},{"key":"1260_CR143","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","volume":"13","author":"DH Ffytche","year":"2017","unstructured":"Ffytche, D. H. et al. The psychosis spectrum in Parkinson disease. Nat. Rev. Neurol. 13, 81\u201395 https:\/\/doi.org\/10.1038\/nrneurol.2016.200 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1260_CR144","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2034634","volume":"385","author":"PN Tariot","year":"2021","unstructured":"Tariot, P. N. et al. Trial of pimavanserin in dementia-related psychosis. N. Engl. J. Med. 385, 309\u2013319 https:\/\/doi.org\/10.1056\/NEJMoa2034634 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR145","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard, C. et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 17, 213\u2013222 https:\/\/doi.org\/10.1016\/s1474-4422(18)30039-5 (2018).","journal-title":"Lancet Neurol."},{"key":"1260_CR146","unstructured":"NIH. A Study to Evaluate Safety and Efficacy of KarXT+KarX-EC as a Treatment for Psychosis Associated with Alzheimer\u2019s Disease (ADEPT-5) (National Institute of Health, 2026); https:\/\/clinicaltrials.gov\/study\/NCT06947941?cond=Alzheimer%20Disease&term=xanomeline&viewType=Card&rank=5."},{"key":"1260_CR147","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0140-6736(11)60830-1","volume":"378","author":"S Banerjee","year":"2011","unstructured":"Banerjee, S. et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 378, 403\u2013411 https:\/\/doi.org\/10.1016\/s0140-6736(11)60830-1 (2011).","journal-title":"Lancet."},{"key":"1260_CR148","doi-asserted-by":"publisher","first-page":"CD003944","DOI":"10.1002\/14651858.CD003944.pub2","volume":"8","author":"R Dudas","year":"2018","unstructured":"Dudas, R., Malouf, R., McCleery, J. & Dening, T. Antidepressants for treating depression in dementia. Cochrane Database Syst. Rev. 8, CD003944 https:\/\/doi.org\/10.1002\/14651858.CD003944.pub2 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1260_CR149","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/02698811211030181","volume":"35","author":"Y He","year":"2021","unstructured":"He, Y. et al. Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: a systematic review and network meta-analysis. J. Psychopharmacol. 35, 901\u2013909 https:\/\/doi.org\/10.1177\/02698811211030181 (2021).","journal-title":"J. Psychopharmacol."},{"key":"1260_CR150","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.4088\/JCP.13086tx5c","volume":"76","author":"GI Papakostas","year":"2015","unstructured":"Papakostas, G. I. Antidepressants and their effect on cognition in major depressive disorder. J. Clin. Psychiatry 76, e1046 https:\/\/doi.org\/10.4088\/JCP.13086tx5c (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"1260_CR151","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/jad-161247","volume":"58","author":"V Orgeta","year":"2017","unstructured":"Orgeta, V., Tabet, N., Nilforooshan, R. & Howard, R. Efficacy of antidepressants for depression in Alzheimer\u2019s disease: systematic review and meta-Analysis. J. Alzheimers Dis. 58, 725\u2013733 https:\/\/doi.org\/10.3233\/jad-161247 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1260_CR152","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1192\/bjp.168.2.149","volume":"168","author":"M Roth","year":"1996","unstructured":"Roth, M., Mountjoy, C. Q. & Amrein, R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br. J. Psychiatry 168, 149\u2013157 https:\/\/doi.org\/10.1192\/bjp.168.2.149 (1996).","journal-title":"Br. J. Psychiatry"},{"key":"1260_CR153","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/psyg.12782","volume":"22","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. Prevalence of mild behavioural impairment domains: a meta-analysis. Psychogeriatrics 22, 84\u201398 https:\/\/doi.org\/10.1111\/psyg.12782 (2022).","journal-title":"Psychogeriatrics"},{"key":"1260_CR154","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jagp.2019.01.215","volume":"27","author":"B Creese","year":"2019","unstructured":"Creese, B. et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am. J. Geriatr. Psychiatry 27, 823\u2013834 https:\/\/doi.org\/10.1016\/j.jagp.2019.01.215 (2019).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1260_CR155","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.inpsyc.2025.100094","volume":"13","author":"B Creese","year":"2025","unstructured":"Creese, B. et al. Pre-psychosis in later life as a risk factor for progressive cognitive decline: findings from the IPA psychosis in neurodegenerative disease working group. Int. Psychogeriatr. 13, 100094 https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100094 (2025).","journal-title":"Int. Psychogeriatr."},{"key":"1260_CR156","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos, C. G. et al. Neuropsychiatric symptoms in Alzheimer\u2019s disease. Alzheimers Dement. 7, 532\u2013539 https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2410 (2011).","journal-title":"Alzheimers Dement."},{"key":"1260_CR157","doi-asserted-by":"publisher","first-page":"CD001191","DOI":"10.1002\/14651858.CD001191.pub4","volume":"9","author":"JS Birks","year":"2015","unstructured":"Birks, J. S., Chong, L. Y. & Grimley Evans, J. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst. Rev. 9, CD001191 https:\/\/doi.org\/10.1002\/14651858.CD001191.pub4 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1260_CR158","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"A Atri","year":"2008","unstructured":"Atri, A., Shaughnessy, L. W., Locascio, J. J. & Growdon, J. H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 22, 209\u2013221 https:\/\/doi.org\/10.1097\/WAD.0b013e31816653bc (2008).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1260_CR159","first-page":"23","volume":"1","author":"G Maher-Edwards","year":"2015","unstructured":"Maher-Edwards, G. et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement. 1, 23\u201336 (2015).","journal-title":"Alzheimers Dement."},{"key":"1260_CR160","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1044\/1092-4388(2004\/085)","volume":"47","author":"SB Chapman","year":"2004","unstructured":"Chapman, S. B., Weiner, M. F., Rackley, A., Hynan, L. S. & Zientz, J. Effects of cognitive-communication stimulation for Alzheimer\u2019s disease patients treated with donepezil. J. Speech Lang. Hear. Res. 47, 1149\u20131163 https:\/\/doi.org\/10.1044\/1092-4388(2004\/085) (2004).","journal-title":"J. Speech Lang. Hear. Res."},{"key":"1260_CR161","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1017\/s1041610216000090","volume":"28","author":"J Huntley","year":"2016","unstructured":"Huntley, J. & Howard, R. The importance of high quality trials of cognitive interventions in Alzheimer\u2019s disease. Int. Psychogeriatr. 28, 705\u2013706 https:\/\/doi.org\/10.1017\/s1041610216000090 (2016).","journal-title":"Int. Psychogeriatr."},{"key":"1260_CR162","doi-asserted-by":"publisher","first-page":"e12273","DOI":"10.1002\/trc2.12273","volume":"8","author":"PJ Nathan","year":"2022","unstructured":"Nathan, P. J. et al. A phase 1b\/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement. 8, e12273 https:\/\/doi.org\/10.1002\/trc2.12273 (2022).","journal-title":"Alzheimers Dement."},{"key":"1260_CR163","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"J Mintzer","year":"2021","unstructured":"Mintzer, J. et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 78, 1324\u20131332 https:\/\/doi.org\/10.1001\/jamaneurol.2021.3356 (2021).","journal-title":"JAMA Neurol."},{"key":"1260_CR164","doi-asserted-by":"publisher","first-page":"101362","DOI":"10.1016\/j.arr.2021.101362","volume":"69","author":"TW Hsu","year":"2021","unstructured":"Hsu, T. W. et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: a systematic review and meta-analysis. Ageing Res. Rev. 69, 101362 https:\/\/doi.org\/10.1016\/j.arr.2021.101362 (2021).","journal-title":"Ageing Res. Rev."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01260-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:32Z","timestamp":1793192492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01260-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":164,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01260-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"10 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. has received honoraria from Acadia, Maplight, Neurocrine, BMS, Roche, TauRx, Abbvie, Exciva, Lilly, GSK and Eisai pharmaceutical companies in the past 36\u2009months. J.L.C. has provided consultation to abbvie, Acadia, ALZpath, AnnovisBio, Artery, Axsome, Biogen, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, IGC, Janssen, Julius Clinical, Kinoxis, Lilly, Lundbeck, LSP\/eqt, Merck (Merck, Sharp and Dohme), MoCA Cognition, Novo Nordisk, NSC Therapeutics, Otsuka, ReMYND, Roche, Sanofi, Scottish Brain Sciences, Signant Health, Simcere, sinaptica, Takeda and UCB therapeutics, assessment and investment companies. J.L.C. is supported by NIA R35AG71476, NIA R25AG083721, NINDS RO1NS139383, Alzheimer\u2019s Disease Drug Discovery Foundation (ADDF), Gates Ventures, Ted and Maria Quirk Endowment and Joy Chambers-Grundy Endowment. Z.I. has served as an adviser\/consultant to CADTH, EISAI, Lilly, Lundbeck\/Otsuka, Novo Nordisk and Roche. A.C. has received honoraria from Suven, Janssen and Sunovion in the past 36\u2009months. P.D. has no conflicts of interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}